[Executive Summary](index=1&type=section&id=Executive%20Summary) [Key Announcements](index=1&type=section&id=Key%20Announcements) Immuneering Corporation reported Q2 2025 financial results and provided significant business updates, including exceptional 6-month overall survival data for atebimetinib in first-line pancreatic cancer, a new U.S. composition of matter patent, and plans for a pivotal trial - Updated OS and PFS data from first-line pancreatic cancer patients (N=34) treated with atebimetinib + mGnP will be shared in Q3 2025, earlier than previously guided[1](index=1&type=chunk) - Exceptional **94% overall survival (OS)** observed at 6 months in the ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34)[1](index=1&type=chunk) - A newly issued U.S. composition of matter patent for atebimetinib is expected to provide exclusivity into **2042**, with potential for patent term extension[1](index=1&type=chunk) - A Request for End of Phase 2 meeting has been submitted to the FDA, with the pivotal trial expected to initiate in **2026**[1](index=1&type=chunk) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) The CEO highlighted the exceptional 6-month OS data for atebimetinib in first-line pancreatic cancer, noting strong interest from pharmaceutical companies and investors, and emphasized the importance of the new patent for maximizing therapeutic potential across multiple indications - The **6-month OS of 94%** for atebimetinib + mGnP in first-line pancreatic cancer compares favorably to the **67% OS** in the pivotal study of standard of care GnP, which dropped to **50% by 8.5 months**[2](index=2&type=chunk) - The exceptional OS data is generating strong interest from leading pharmaceutical companies and top-tier investors[2](index=2&type=chunk) - The granting of the composition of matter patent for atebimetinib is a significant milestone, expected to support efforts to maximize its therapeutic potential across multiple indications[2](index=2&type=chunk) [Corporate Highlights & Business Updates](index=1&type=section&id=Corporate%20Highlights) [Atebimetinib Clinical Trial Updates](index=1&type=section&id=Atebimetinib%20Clinical%20Trial%20Updates) Immuneering reported positive data from its Phase 2a trial in first-line pancreatic cancer, showing high OS and PFS at 6 months, and provided an update on a long-term responder in the Phase 1 trial for third-line pancreatic cancer [First-Line Pancreatic Cancer (Phase 2a)](index=1&type=section&id=First-Line%20Pancreatic%20Cancer%20(Phase%202a)) Phase 2a Trial Results (Atebimetinib + mGnP in First-Line Pancreatic Cancer at 6 months) | Metric | Value | | :----- | :---- | | OS | 94% | | PFS | 72% | - Median OS and PFS have not yet been reached[3](index=3&type=chunk) - A markedly favorable tolerability profile was observed[3](index=3&type=chunk) - The company plans to initiate a pivotal trial in **2026**, subject to regulatory feedback[3](index=3&type=chunk) [Third-Line Pancreatic Cancer (Phase 1 Monotherapy)](index=2&type=section&id=Third-Line%20Pancreatic%20Cancer%20(Phase%201%20Monotherapy)) - A third-line pancreatic cancer patient has received atebimetinib monotherapy for over **18 months** and remains on treatment[8](index=8&type=chunk) - The patient maintained a partial response, including a **34% reduction** in target lesions (RECIST sum of longest diameters) and a **96% reduction** in peak CA 19-9 levels[8](index=8&type=chunk) - Treatment continued to be well tolerated, with a **~16% weight gain** observed[8](index=8&type=chunk) [Intellectual Property & Regulatory Milestones](index=1&type=section&id=Intellectual%20Property%20%26%20Regulatory%20Milestones) Immuneering secured a key U.S. composition of matter patent for atebimetinib, extending exclusivity into 2042, and has submitted an End of Phase 2 meeting request to the FDA, signaling progress towards a pivotal trial - A U.S. composition of matter patent for atebimetinib was granted in July, providing exclusivity into **2042**, with potential for patent term extension[1](index=1&type=chunk)[8](index=8&type=chunk) - This is the first U.S. patent granted for a deep cyclic inhibitor, designed to drive longer-lasting benefit by outpacing resistance mechanisms[8](index=8&type=chunk) - Additional patent applications for atebimetinib are pending, directed to compounds, pharmaceutical compositions, and methods of use, with expiration expected into **2044**[8](index=8&type=chunk) - An End of Phase 2 meeting request has been submitted to the FDA[1](index=1&type=chunk)[2](index=2&type=chunk) [Near-Term Milestone Expectations](index=2&type=section&id=Near-Term%20Milestone%20Expectations) Immuneering anticipates several key milestones for atebimetinib, including sharing updated clinical data in Q3 2025, receiving regulatory feedback in Q4 2025, and initiating a pivotal trial and additional combination arms in 2026 - Upcoming milestones include: * Announce updated OS and PFS data from first-line pancreatic cancer patients (n=34) treated with atebimetinib + mGnP in **Q3 2025**[8](index=8&type=chunk) * Receive regulatory feedback on pivotal study plans in **Q4 2025**[8](index=8&type=chunk) * Initiate pivotal, randomized trial of atebimetinib in combination with mGnP in first-line pancreatic cancer in **2026**[8](index=8&type=chunk) * Initiate additional atebimetinib clinical trial combination arms in **2026**[8](index=8&type=chunk) [Financial Results (Second Quarter 2025)](index=2&type=section&id=Financial%20Results%20(Second%20Quarter%202025)) [Financial Highlights](index=2&type=section&id=Financial%20Highlights) Immuneering reported a decrease in cash and cash equivalents, a slight decrease in R&D expenses, consistent G&A expenses, and an increased net loss for Q2 2025 compared to the prior year [Cash Position](index=2&type=section&id=Cash%20Position) Cash and Cash Equivalents | Metric | June 30, 2025 | December 31, 2024 | Change | | :----- | :------------ | :---------------- | :----- | | Amount | $26.4 million | $36.1 million | -$9.7 million | [Operating Expenses](index=2&type=section&id=Operating%20Expenses) Operating Expenses (Three Months Ended June 30) | Expense Type | 2025 (USD) | 2024 (USD) | Change (YoY, USD) | | :----------- | :------------ | :------------ | :---------------- | | R&D Expenses | $10.5 million | $10.7 million | -$0.2 million | | G&A Expenses | $4.3 million | $4.3 million | $0 million | - The decrease in R&D expenses was primarily attributable to decreases in spend for preclinical programs, the IMM-6-415 program, and personnel costs, offset by higher clinical costs related to the atebimetinib program[5](index=5&type=chunk) - G&A expenses for Q2 2025 were consistent with the comparable prior period[6](index=6&type=chunk) [Net Loss](index=2&type=section&id=Net%20Loss) Net Loss (Three Months Ended June 30) | Metric | 2025 (USD) | 2024 (USD) | Change (YoY, USD) | | :----- | :------------ | :------------ | :---------------- | | Net Loss | $14.4 million | $14.1 million | +$0.3 million | | EPS | $0.40 | $0.47 | -$0.07 | [2025 Financial Guidance](index=2&type=section&id=2025%20Financial%20Guidance) Based on current cash and operating plans, Immuneering expects its cash runway to be sufficient to fund operations into 2026 - Cash and cash equivalents as of June 30, 2025, are expected to fund operations into **2026**[7](index=7&type=chunk) [About Immuneering Corporation](index=3&type=section&id=About%20Immuneering%20Corporation) [Company Overview](index=3&type=section&id=Company%20Overview) Immuneering is a clinical-stage oncology company focused on developing treatments that outpace cancer. Its lead candidate, atebimetinib, is an oral MEK inhibitor in Phase 2a for advanced solid tumors, including pancreatic cancer, with early-stage programs also in its pipeline - Immuneering is a clinical-stage oncology company focused on outpacing cancer to help patients outlive their disease[9](index=9&type=chunk) - The Company's lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of MEK[9](index=9&type=chunk) - Atebimetinib is designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers[9](index=9&type=chunk) - Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer, and the Company's development pipeline also includes early-stage programs[9](index=9&type=chunk) [Forward-Looking Statements & Risks](index=3&type=section&id=Forward-Looking%20Statements%20%26%20Risks) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements regarding product development, clinical trials, regulatory approvals, intellectual property, and financial outlook, along with a disclaimer outlining inherent risks and uncertainties that could cause actual results to differ materially - Statements include plans for product candidate development, treatment potential of atebimetinib, timing of clinical trials and regulatory feedback, cash runway expectations, and patent expiration[10](index=10&type=chunk) - These statements are subject to known and unknown risks, uncertainties, and other important factors, including those inherent in oncology drug R&D, funding needs, regulatory processes, reliance on third parties, competition, and intellectual property protection[11](index=11&type=chunk) - Readers are cautioned not to rely on these statements as representing views beyond the press release date, and the company disclaims any obligation to update them, except as required by law[12](index=12&type=chunk) [Contact Information](index=4&type=section&id=Contact%20Information) [Contact Details](index=4&type=section&id=Contact%20Details) Provides contact details for media and investor inquiries - Media Contact: Gina Nugent (Gina.nugent.external@immuneering.com)[13](index=13&type=chunk) - Investor Contact: Laurence Watts (619-916-7620, laurence@newstreetir.com)[13](index=13&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) This statement presents the company's revenues, expenses, and net loss for the three and six months ended June 30, 2025, and 2024, showing an increase in net loss for both periods Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | Metric | Three Months Ended June 30, 2025 (USD) | Three Months Ended June 30, 2024 (USD) | Six Months Ended June 30, 2025 (USD) | Six Months Ended June 30, 2024 (USD) | | :------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $10,454,160 | $10,651,958 | $21,925,852 | $21,854,372 | | General and administrative | $4,296,417 | $4,254,473 | $8,302,059 | $8,370,493 | | Total operating expenses | $14,757,894 | $14,913,748 | $30,242,544 | $30,239,498 | | Net loss | $(14,433,881) | $(14,079,927) | $(29,480,012) | $(28,387,756) | | Net loss per share (basic and diluted)| $(0.40) | $(0.47) | $(0.82) | $(0.96) | | Weighted-average common shares outstanding | 35,985,878 | 29,653,355 | 35,759,026 | 29,511,856 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) This statement provides a snapshot of the company's assets, liabilities, and stockholders' equity as of June 30, 2025, and December 31, 2024, indicating a decrease in total assets and stockholders' equity Condensed Consolidated Balance Sheets (Unaudited) | Metric | June 30, 2025 (USD) | December 31, 2024 (USD) | | :------------------------------------ | :------------ | :---------------- | | Cash and cash equivalents | $26,355,498 | $36,144,720 | | Total current assets | $27,725,426 | $39,587,569 | | Total assets | $40,056,468 | $52,714,413 | | Total current liabilities | $7,486,830 | $7,503,768 | | Total liabilities | $11,120,431 | $11,328,187 | | Total stockholders' equity | $28,936,037 | $41,386,226 |

[Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) Ibotta's Q2 2025 featured a 2% revenue decline, a net income turnaround, and robust IPN redeemer growth driven by third-party publishers [Q2 2025 Financial Highlights](index=1&type=section&id=Q2%202025%20Financial%20Highlights) Q2 2025 saw a 2% revenue decrease, a shift to $2.5 million net income, and a 29% Adjusted EBITDA decline, alongside significant share repurchases Q2 2025 Key Financial Metrics (YoY) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | **Revenue** | $86.0M | $87.9M | (2)% | | **Redemption Revenue** | $73.2M | $74.0M | (1)% | | **Net Income (Loss)** | $2.5M | ($34.0M) | 107% | | **Adjusted EBITDA** | $17.9M | $25.3M | (29)% | | **Adjusted EBITDA Margin** | 21% | 29% | - | | **Free Cash Flow** | $18.9M | $32.7M | (42)% | - The company repurchased **1.4 million shares** for a total of **$67.5 million** at an average price of **$46.59 per share** during the quarter[6](index=6&type=chunk) [Q2 2025 Operational & Business Highlights](index=1&type=section&id=Q2%202025%20Operational%20%26%20Business%20Highlights) IPN total redeemers grew 27% to 17.3 million, driven by third-party publishers, while direct-to-consumer redeemers declined, alongside DoorDash expansion Q2 2025 Key Performance Metrics (YoY) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | **Total Redeemers** | 17.3M | 13.7M | 27% | | - Direct-to-consumer | 1.6M | 1.8M | (11)% | | - Third-party publisher | 15.7M | 11.9M | 32% | | **Total Redemptions** | 80.5M | 80.7M | 0% | | - Direct-to-consumer | 21.9M | 28.6M | (23)% | | - Third-party publisher | 58.6M | 52.1M | 12% | - Key business developments in Q2 2025 include[8](index=8&type=chunk): - Ibotta digital offers became available to the majority of DoorDash customers - Strengthened the revenue leadership team with new hires for SVP of Enterprise Sales and SVP of Business Marketing - Implemented a sales re-organization to support the transition to performance marketing [Financial Guidance](index=4&type=section&id=Financial%20Guidance) Ibotta projects Q3 2025 revenue between $79.0 million and $84.0 million, a 17% YoY decrease at midpoint, with Adjusted EBITDA of $9.5 million to $13.5 million Third Quarter 2025 Outlook | Metric | Guidance Range | Midpoint YoY Change | | :--- | :--- | :--- | | **Revenue** | $79.0M - $84.0M | (17)% | | **Adjusted EBITDA** | $9.5M - $13.5M | - | | **Adjusted EBITDA Margin** | ~14% (at midpoint) | - | - Ibotta has not reconciled its Adjusted EBITDA guidance to GAAP net income because certain items, such as share-based compensation, are uncertain and cannot be reasonably predicted[9](index=9&type=chunk) [Consolidated Financial Statements](index=8&type=section&id=Consolidated%20Financial%20Statements) This section presents Ibotta's unaudited condensed financial statements, including Statements of Operations, Balance Sheets, and Cash Flows, for Q2 2025 and year-to-date [Condensed Statements of Operations](index=8&type=section&id=Condensed%20Statements%20of%20Operations) Q2 2025 saw $86.0 million revenue, $68.1 million gross profit, and a shift to $1.2 million operating income, driven by reduced operating expenses Q2 2025 Statement of Operations Highlights (in thousands) | Line Item | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | **Revenue** | $86,029 | $87,926 | (2.2)% | | **Gross Profit** | $68,104 | $75,643 | (10.0)% | | **Total Operating Expenses** | $66,866 | $97,300 | (31.3)% | | **Income (Loss) from Operations** | $1,238 | ($21,657) | 105.7% | | **Net Income (Loss)** | $2,490 | ($33,966) | 107.3% | - Stock-based compensation expense decreased significantly to **$13.6 million** in Q2 2025 from **$44.8 million** in Q2 2024, contributing to lower operating expenses[21](index=21&type=chunk) [Condensed Balance Sheets](index=9&type=section&id=Condensed%20Balance%20Sheets) As of June 30, 2025, Ibotta's cash and equivalents decreased to $250.5 million, with total assets at $600.8 million and stockholders' equity at $354.1 million Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $250,549 | $349,282 | | **Total current assets** | $482,647 | $581,741 | | **Total assets** | $600,778 | $678,429 | | **Total current liabilities** | $204,033 | $204,165 | | **Total liabilities** | $246,650 | $221,146 | | **Total stockholders' equity** | $354,128 | $457,283 | [Condensed Statements of Cash Flows](index=10&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, operating cash flow was $45.7 million, with significant cash usage in financing activities, primarily for treasury stock purchases Six Months Ended June 30 Cash Flow Summary (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $45,715 | $54,386 | | **Net cash used in investing activities** | ($11,968) | ($4,789) | | **Net cash (used in) provided by financing activities** | ($132,830) | $205,670 | | **Net change in cash** | ($99,083) | $255,267 | [Supplemental Financial Information](index=11&type=section&id=Supplemental%20Financial%20Information) This section provides detailed revenue breakdowns by channel and reconciliations of GAAP to non-GAAP financial measures, highlighting a strategic shift towards third-party publishers [Supplemental Revenue Detail](index=11&type=section&id=Supplemental%20Revenue%20Detail) Q2 2025 saw third-party publisher revenue grow 17% to $48.6 million, offsetting a 19% decline in direct-to-consumer revenue, indicating a strategic shift Q2 Revenue by Channel (in thousands, YoY) | Revenue Source | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | **Direct-to-consumer** | $37,441 | $46,275 | (19)% | | **Third-party publishers** | $48,588 | $41,651 | 17% | | **Total Revenue** | $86,029 | $87,926 | (2)% | [Reconciliation of Non-GAAP Financial Measures](index=12&type=section&id=Reconciliation%20of%20Non-GAAP%20Financial%20Measures) This section reconciles GAAP net income to non-GAAP metrics, showing Q2 2025 Adjusted EBITDA of $17.9 million and Adjusted Net Income of $14.9 million Q2 Reconciliation of Net Income (Loss) to Adjusted EBITDA (in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net income (loss)** | $2,490 | ($33,966) | | Stock-based compensation | $13,642 | $44,817 | | Other adjustments | $1,745 | $14,623 | | **Adjusted EBITDA** | $17,882 | $25,274 | Q2 Reconciliation of Adjusted Net Income (in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net income (loss)** | $2,490 | ($33,966) | | Stock-based compensation & other adjustments | $14,199 | $55,832 | | Adjustment for income taxes | ($1,797) | ($2,007) | | **Adjusted net income** | $14,892 | $19,859 | Q2 Reconciliation of Free Cash Flow (in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $25,855 | $35,020 | | Additions to property & capitalized software | ($7,000) | ($2,322) | | **Free cash flow** | $18,855 | $32,698 | [About Ibotta & Key Definitions](index=6&type=section&id=About%20Ibotta%20%26%20Key%20Definitions) Ibotta operates the AI-powered Ibotta Performance Network (IPN) for CPG digital promotions, defining key terms like Redeemers, Redemptions, and Redemption Revenue - Ibotta's business is centered on its **Ibotta Performance Network (IPN)**, an AI-enabled platform for CPG brands to deliver digital promotions on a pay-for-performance (fee-per-sale) basis[15](index=15&type=chunk)[18](index=18&type=chunk) - Key terms defined[16](index=16&type=chunk)[17](index=17&type=chunk): - **Redeemers:** A consumer who has redeemed at least one digital offer in a period - **Redemptions:** A verified purchase of an item qualifying for an offer - **Redemption Revenue:** The fee earned per redemption

[Vaxart Q2 2025 Business Update and Financial Results](index=1&type=section&id=Vaxart%20Q2%202025%20Business%20Update%20and%20Financial%20Results) [Recent Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) Vaxart reported significant progress across its vaccine pipeline, including its norovirus, COVID-19, and influenza programs [Norovirus Vaccine Developments](index=1&type=section&id=Norovirus%20Vaccine%20Developments) - Positive topline data from the Phase 1 trial of the second-generation oral norovirus vaccine showed **statistically significant increases in GI.1 (141%) and GII.4 (94%) norovirus blocking antibodies** compared to the first-generation constructs[1](index=1&type=chunk)[5](index=5&type=chunk) - The company is in discussions with potential partners to support a Phase 2b trial, which could begin as early as the **second half of 2025**, with a potential Phase 3 trial starting in **2026**[4](index=4&type=chunk)[5](index=5&type=chunk) [COVID-19 Vaccine Developments](index=2&type=section&id=COVID-19%20Vaccine%20Developments) - On August 5, 2025, Vaxart received a stop work order for screening and enrollment in its COVID-19 Phase 2b trial, after approximately **5,000 participants** had been enrolled[1](index=1&type=chunk)[4](index=4&type=chunk)[9](index=9&type=chunk) - Follow-up for all dosed participants will continue, with data from a 400-person sentinel cohort expected in **Q1 2026** and overall topline data in **late 2026**[1](index=1&type=chunk)[9](index=9&type=chunk) [Influenza Program Developments](index=2&type=section&id=Influenza%20Program%20Developments) - The new avian influenza vaccine candidate was **100% protective against death** in a ferret challenge model, compared to **0% survival** in the placebo group[7](index=7&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Financial%20Results%20for%20the%20Second%20Quarter%20Ended%20June%2030%2C%202025) The company reported a significant revenue increase to $39.7 million and a narrowed net loss, ending the quarter with a cash runway into Q1 2026 Q2 2025 Financial Highlights | Financial Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue | $39.7 million | $6.4 million | | Research & Development Expenses | $49.7 million | $17.5 million | | General & Administrative Expenses | $4.6 million | $5.2 million | | Net Loss | $15.0 million | $16.5 million | | Net Loss Per Share | $0.07 | $0.09 | - Cash, cash equivalents, and investments totaled **$26.3 million** as of June 30, 2025, with an anticipated cash runway into the **first quarter of 2026**[1](index=1&type=chunk)[9](index=9&type=chunk) - The increase in revenue was primarily from government contracts related to the **BARDA contract** awarded in June 2024[9](index=9&type=chunk) - The rise in R&D expenses was mainly driven by increased clinical trial costs for the **COVID-19 and norovirus vaccine candidates**[9](index=9&type=chunk) [Corporate Updates and Events](index=1&type=section&id=Corporate%20Updates%20and%20Events) Vaxart announced an upcoming conference call and a special stockholder meeting to vote on a potential reverse stock split - A virtual special meeting of stockholders is scheduled for **September 5, 2025**, to seek approval for a **reverse stock split**[11](index=11&type=chunk) - The proposed reverse stock split ratio would be between **1-for-5 and 1-for-20**, aimed at regaining compliance with Nasdaq's minimum bid price requirement[14](index=14&type=chunk) - A conference call to discuss Q2 2025 results is scheduled for **August 13, 2025**, and a live stockholder fireside chat will be held on **August 20, 2025**[2](index=2&type=chunk)[3](index=3&type=chunk)[12](index=12&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents the unaudited condensed consolidated balance sheets and statements of operations as of June 30, 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance Sheet Summary | Balance Sheet Item (in thousands) | June 30, 2025 (Unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $20,111 | $25,230 | | Total assets | $164,085 | $166,391 | | **Liabilities & Equity** | | | | Total liabilities | $131,207 | $107,465 | | Stockholders' equity | $32,878 | $58,926 | | Total liabilities and stockholders' equity | $164,085 | $166,391 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Three Months Ended June 30 | Statement of Operations (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $39,730 | $6,401 | | Total operating expenses | $54,333 | $22,657 | | Operating loss | ($14,603) | ($16,256) | | Net loss | ($14,986) | ($16,466) | Six Months Ended June 30 | Statement of Operations (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $60,606 | $8,582 | | Total operating expenses | $90,144 | $48,908 | | Operating loss | ($29,538) | ($40,326) | | Net loss | ($30,577) | ($40,883) |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35947 Star Equity Holdings, Inc. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35947 Star Equity Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0145723 53 Forest Ave., Suite 1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission Fil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2025 Date of Report (date of earliest event reported) ___________________________________ Greenidge Generation Holdings Inc. (Exact name of registrant as specified in its charter) ___________________________________ 001-40808 (Commission File Number) 86-1746728 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: ____________to ____________ _____________________ EMPIRE PETROLEUM CORPORATION (Exact name of registrant as specified in its charter) _____________________ FORM ...

Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO- 207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-41272 HeartCore Enterprises, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0913420 (State ...